Clarifying Clinical Causal Relationships Based on Genomic Cohort Data of 156,000 Individuals
Vasgen Bio, an AI-based bio big data specialist company led by CEO Kim Ho, announced that it has been selected for the "Global Technology Commercialization Support Project" hosted by the Korea Technology Venture Foundation.
The Global Technology Commercialization Support Project is a program by the Korea Institute for Advancement of Technology that supports overseas technology transfer and commercialization through Global Commercialization Cooperation Centers (GCC) designated in major foreign countries to help domestic technologies, facilities, and products enter overseas markets.
Vasgen Bio has chosen biomarker discovery and full-cycle new drug development efficiency solutions based on genomic cohort data of 156,000 individuals as its global core business. The biomarker with a time concept, "TLBM (Time-Labeled Biomarker)," and the full-cycle new drug development efficiency solution "DEEPCT (Deep learning based Clinical Trial)" form a business model covering the entire process from disease occurrence prediction, prevention, treatment, to prognosis management, leading the pharmaceutical and bio market in new drug development and predictive diagnostics efficiency.
Recently, the pharmaceutical and bio industries have been focusing on new drug development using artificial intelligence. However, they face difficulties in securing genomic data, which is the essential source for research and development. In contrast, Vasgen Bio received high praise for exclusively securing Korean genomic cohort data tracked for over 17 years. This genomic cohort data includes not only genetic information but also screening and disease diagnosis information, making it optimized for precision medicine technology development.
Lee Sol, Director of Vasgen Bio’s Genetic Epidemiology Research Institute, stated, “We are honored to be selected for this support project, allowing us to enter the global market and showcase innovative bioindustry technologies based on Korean genomic cohort data. Through drug efficacy prediction and complex drug design and verification technologies, we will solve many new drug development challenges that have not been addressed so far.”
She also predicted, “Through various research and development efforts such as the advancement of already discovered biomarkers and the discovery of new biomarkers incorporating the time concept, we will provide indispensable technologies to the pharmaceutical and bio industries.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
